Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MMRF’s MyDRUG Platform Trial Aims For Efficiency In Testing Treatments For Myeloma Mutations

Executive Summary

The adaptive trial design will help test smaller subpopulations and could lead to more effective and cost-efficient treatment strategies.

You may also be interested in...



Multiple Myeloma: Pricing And Reimbursement Challenges Escalate Even As Blockbusters Go Generic

As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.

Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake

CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them. 

Genomics-Driven Trials Built To Be Fast And Flexible

Pioneering enrollment strategies are coupled with adaptive statistical designs in the next wave of basket trials from NCI, ASCO and Novartis.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel